Cargando…

Effect of once weekly dulaglutide by baseline beta‐cell function in people with type 2 diabetes in the AWARD programme

Glucagon‐like peptide‐1 receptor agonists lower blood glucose in type 2 diabetes (T2D) partially through glucose‐dependent stimulation of insulin secretion. The aim of this study was to investigate whether beta‐cell function (as measured by HOMA2‐%B) at baseline affects the glycaemic response to dul...

Descripción completa

Detalles Bibliográficos
Autores principales: Mathieu, Chantal, Del Prato, Stefano, Botros, Fady T., Thieu, Vivian T., Pavo, Imre, Jia, Nan, Haupt, Axel, Karanikas, Chrisanthi A., García‐Pérez, Luis‐Emilio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6055818/
https://www.ncbi.nlm.nih.gov/pubmed/29603872
http://dx.doi.org/10.1111/dom.13313
_version_ 1783341255050133504
author Mathieu, Chantal
Del Prato, Stefano
Botros, Fady T.
Thieu, Vivian T.
Pavo, Imre
Jia, Nan
Haupt, Axel
Karanikas, Chrisanthi A.
García‐Pérez, Luis‐Emilio
author_facet Mathieu, Chantal
Del Prato, Stefano
Botros, Fady T.
Thieu, Vivian T.
Pavo, Imre
Jia, Nan
Haupt, Axel
Karanikas, Chrisanthi A.
García‐Pérez, Luis‐Emilio
author_sort Mathieu, Chantal
collection PubMed
description Glucagon‐like peptide‐1 receptor agonists lower blood glucose in type 2 diabetes (T2D) partially through glucose‐dependent stimulation of insulin secretion. The aim of this study was to investigate whether beta‐cell function (as measured by HOMA2‐%B) at baseline affects the glycaemic response to dulaglutide. Dulaglutide‐treated patients from AWARD‐1, AWARD‐3 and AWARD‐6 clinical studies were categorised based on their homeostatic model assessment of beta‐cell function (HOMA2‐%B) tertiles. Changes in glycaemic measures in response to treatment with once‐weekly dulaglutide were evaluated in each HOMA2‐%B tertile. Patients with low HOMA2‐%B had higher baseline glycated haemoglobin (HbA1c), fasting and postprandial blood glucose, and longer duration of diabetes (P < .001, all) (mean low, middle and high tertiles with dulaglutide 1.5 mg: HOMAB‐2%B, 31%, 58%, 109%; HbA1c, 8.7%, 7.7%, 7.3%, respectively). At 26 weeks, the low tertile experienced larger reductions in HbA1c compared to the high tertile with dulaglutide 1.5 mg (mean; −1.55% vs. −0.98% [−16.94 vs. −10.71 mmol/mol]). Differences between low and high tertiles disappeared when adjusted for baseline HbA1c (LSM; −1.00 vs. −1.18% [−10.93 vs. −12.90 mmol/mol]). Greater decreases in fasting blood glucose and greater increases in fasting C‐peptide were observed in the low tertile. Similar increases in HOMA2‐%B were observed in all tertiles. Dulaglutide demonstrated clinically relevant HbA1c reduction irrespective of estimated baseline beta‐cell function.
format Online
Article
Text
id pubmed-6055818
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Blackwell Publishing Ltd
record_format MEDLINE/PubMed
spelling pubmed-60558182018-07-30 Effect of once weekly dulaglutide by baseline beta‐cell function in people with type 2 diabetes in the AWARD programme Mathieu, Chantal Del Prato, Stefano Botros, Fady T. Thieu, Vivian T. Pavo, Imre Jia, Nan Haupt, Axel Karanikas, Chrisanthi A. García‐Pérez, Luis‐Emilio Diabetes Obes Metab Brief Reports Glucagon‐like peptide‐1 receptor agonists lower blood glucose in type 2 diabetes (T2D) partially through glucose‐dependent stimulation of insulin secretion. The aim of this study was to investigate whether beta‐cell function (as measured by HOMA2‐%B) at baseline affects the glycaemic response to dulaglutide. Dulaglutide‐treated patients from AWARD‐1, AWARD‐3 and AWARD‐6 clinical studies were categorised based on their homeostatic model assessment of beta‐cell function (HOMA2‐%B) tertiles. Changes in glycaemic measures in response to treatment with once‐weekly dulaglutide were evaluated in each HOMA2‐%B tertile. Patients with low HOMA2‐%B had higher baseline glycated haemoglobin (HbA1c), fasting and postprandial blood glucose, and longer duration of diabetes (P < .001, all) (mean low, middle and high tertiles with dulaglutide 1.5 mg: HOMAB‐2%B, 31%, 58%, 109%; HbA1c, 8.7%, 7.7%, 7.3%, respectively). At 26 weeks, the low tertile experienced larger reductions in HbA1c compared to the high tertile with dulaglutide 1.5 mg (mean; −1.55% vs. −0.98% [−16.94 vs. −10.71 mmol/mol]). Differences between low and high tertiles disappeared when adjusted for baseline HbA1c (LSM; −1.00 vs. −1.18% [−10.93 vs. −12.90 mmol/mol]). Greater decreases in fasting blood glucose and greater increases in fasting C‐peptide were observed in the low tertile. Similar increases in HOMA2‐%B were observed in all tertiles. Dulaglutide demonstrated clinically relevant HbA1c reduction irrespective of estimated baseline beta‐cell function. Blackwell Publishing Ltd 2018-05-02 2018-08 /pmc/articles/PMC6055818/ /pubmed/29603872 http://dx.doi.org/10.1111/dom.13313 Text en © 2018 The Authors. Diabetes, Obesity and Metabolism published by John Wiley & Sons Ltd. This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Brief Reports
Mathieu, Chantal
Del Prato, Stefano
Botros, Fady T.
Thieu, Vivian T.
Pavo, Imre
Jia, Nan
Haupt, Axel
Karanikas, Chrisanthi A.
García‐Pérez, Luis‐Emilio
Effect of once weekly dulaglutide by baseline beta‐cell function in people with type 2 diabetes in the AWARD programme
title Effect of once weekly dulaglutide by baseline beta‐cell function in people with type 2 diabetes in the AWARD programme
title_full Effect of once weekly dulaglutide by baseline beta‐cell function in people with type 2 diabetes in the AWARD programme
title_fullStr Effect of once weekly dulaglutide by baseline beta‐cell function in people with type 2 diabetes in the AWARD programme
title_full_unstemmed Effect of once weekly dulaglutide by baseline beta‐cell function in people with type 2 diabetes in the AWARD programme
title_short Effect of once weekly dulaglutide by baseline beta‐cell function in people with type 2 diabetes in the AWARD programme
title_sort effect of once weekly dulaglutide by baseline beta‐cell function in people with type 2 diabetes in the award programme
topic Brief Reports
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6055818/
https://www.ncbi.nlm.nih.gov/pubmed/29603872
http://dx.doi.org/10.1111/dom.13313
work_keys_str_mv AT mathieuchantal effectofonceweeklydulaglutidebybaselinebetacellfunctioninpeoplewithtype2diabetesintheawardprogramme
AT delpratostefano effectofonceweeklydulaglutidebybaselinebetacellfunctioninpeoplewithtype2diabetesintheawardprogramme
AT botrosfadyt effectofonceweeklydulaglutidebybaselinebetacellfunctioninpeoplewithtype2diabetesintheawardprogramme
AT thieuviviant effectofonceweeklydulaglutidebybaselinebetacellfunctioninpeoplewithtype2diabetesintheawardprogramme
AT pavoimre effectofonceweeklydulaglutidebybaselinebetacellfunctioninpeoplewithtype2diabetesintheawardprogramme
AT jianan effectofonceweeklydulaglutidebybaselinebetacellfunctioninpeoplewithtype2diabetesintheawardprogramme
AT hauptaxel effectofonceweeklydulaglutidebybaselinebetacellfunctioninpeoplewithtype2diabetesintheawardprogramme
AT karanikaschrisanthia effectofonceweeklydulaglutidebybaselinebetacellfunctioninpeoplewithtype2diabetesintheawardprogramme
AT garciaperezluisemilio effectofonceweeklydulaglutidebybaselinebetacellfunctioninpeoplewithtype2diabetesintheawardprogramme